View Author
patient trial mortality study level troponin treatment infarction syndrome death outcome heart elevation 30 days /iiia group baseline abciximab table angina result therapy glycoprotein analysis event disease artery effect intervention model troponin t difference ratio investigator gusto placebo circulation ck-mb platelet -15 characteristic value inhibitor 1- year mortality revascularisation 30- hospital heparin receptor st-segment gdf -15 levels survival gdf -15 randomized pursuit percutaneou artery disease cohort factor relation nt-probnp quartile marker dalteparin st-segment elevation prognostic heart failure history predictor baseline characteristics follow-up signi infusion strategy randomization nste-ac assay st 2 levels 0.001 revascularization
10 Most Recent Publications
|
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years
(Article)
Chan, M.Y. Sun, J.L. Pieper, K.S. Giugliano, R.P. Armstrong, P.W. Califf, R.M. Werf, F.J.J. van de Harrington, R.A. Newby, L.K. Lokhnygina, Y. White, H.D. Moliterno, D.J. Theroux, P. Ohman, E.M. Simoons, M.L. Mahaffey, K.W. |
2012-02-16
|
|
The future of clinical trials in secondary prevention after acute coronary syndromes
(Article)
Bueno, H. Armstrong, P.W. Steg, P.G. Buxton, M.J. Danchin, N. Lubsen, J. Roland, E. Verheugt, F.W.A. Zalewski, A. Jackson, N.C. Komajda, M. |
2011-07-01
|
|
ST2 and mortality in non-ST-segment elevation acute coronary syndrome
(Article)
Eggers, K.M. Armstrong, P.W. Califf, R.M. Simoons, M.L. Venge, P. Wallentin, L.C. James, S.K. |
2010-05-01
|
|
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups
(Article)
Hernández A.V. Westerhout, C.M. Simoons, M.L. Boersma, H. Steyerberg, E.W. Bueno, H. White, H.D. Théroux, P. Moliterno, D.J. Armstrong, P.W. Califf, R.M. Wallentin, L.C. |
2008-03-14
|
|
No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: Insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial
(Article)
Westerhout, C.M. Gnarpe, J. Chang, W.C. FitzPatrick, S. Barnathan, E.S. Boersma, H. Califf, R.M. Wallentin, L.C. Simoons, M.L. Armstrong, P.W. |
2007-08-01
|
|
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome
(Article)
Wollert, K.C. Kempf, T. Armstrong, P.W. Califf, R.M. Drexler, H. Wallentin, L.C. Peter, T. Olofsson, S. James, S.K. Johnston, N. Lindahl, B. Horn-Wichmann, R. Brabant, G. Simoons, M.L. |
2007-02-01
|
|
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.
(Article)
Labinaz, M. Mathias, J. Califf, R.M. Topol, E.J. Harrington, R.A. Armstrong, P.W. Pieper, K.S. Granger, C.B. Lincoff, A.M. Moliterno, D.J. Werf, F.J.J. van de Simes, R.J. White, H.D. Simoons, M.L. |
2005-01-01
|
|
Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis
(Article)
Chang, W.C. Midodzi, W.K. Westerhout, C.M. Cooper, J. Barnathan, E.S. Simoons, M.L. Wallentin, L.C. Ohman, E.M. Armstrong, P.W. Boersma, H. |
2005-01-01
|
|
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS.
(Article)
Ottervanger, J.P. Barnathan, E.S. Boersma, H. Cooper, J.S. Ohman, E.M. James, S.K. Wallentin, L.C. Simoons, M.L. Armstrong, P.W. |
2004-09-01
|
|
Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS
(Article)
Lenderink, T. Ruzyllo, W. Widimsky, P. Ohman, E.M. Armstrong, P.W. Wallentin, L.C. Simoons, M.L. Boersma, H. |
2004-05-01
|
